FGFR2 and infantile convulsions and choreoathetosis: First, the identification of FGFR fusions has been associated with the onset of iCCA, and two FGFR-targeted agents, infigratinib and pemigatinib, have been approved by the United States Food and Drug Administration (FDA) following the results of phase II trials assessing these FGFR inhibitors in previously treated patients with FGFR2 gene fusions or rearrangements [30].